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ABSTRACT 
 
 Disruptions in methyl group metabolism have been associated with a number of disease states, 
including birth defects, cardiovascular disease, and neurological disorders. Therefore, characterization of 
the factors that regulate folate and methyl group supply is essential for the development of disease 
treatments and prevention. Glycine N-methyltransferase (GNMT), an enzyme essential to methyl group 
balance, is markedly increased by retinoic acid treatment. Furthermore, retinoid therapy has been 
shown to impact neurotransmitter metabolism, thereby contributing to the development of major 
depressive disorder. Recently, it has been shown that depressed patients have low levels of folate, other 
B-vitamins, and S-adenosyl methionine (SAM), all compounds essential for maintaining effective methyl 
group metabolism. The following studies were conducted to further characterize the impact of oral 
retinoic acid administration, and to investigate the potential prevention of any detrimental effects by 
administering oral SAM. In the preliminary study (Chapter 2), as expected, GNMT activity was 
significantly increased in rats receiving all-trans retinoic acid (ATRA). Additionally, whole brain serotonin 
levels were decreased by 46% in rats receiving ATRA, an effect that was partially attenuated by oral 
SAM.  
The experiment was repeated with an improved dosing method, longer duration of treatment, 
and another form of retinoic acid, 13-cis retinoic acid (13CRA). Retinoic acid was shown to increase liver 
lipids and triglycerides, decrease hepatic SAM, and mildly elevate serotonin, in contrast to the first 
experiment. ATRA slightly decreased whole brain dopamine transporter (DAT) and 13CRA slightly 
decreased whole brain norepinephrine transporter (NET); these effects were not seen in rats that 
received supplemental SAM. Furthermore, SAM abrogated liver lipid content in rats receiving 13CRA, 
partially prevented increases in liver triglycerides, and restored hepatic SAM levels in both retinoic acid 
groups. Rats that received only SAM supplementation had extremely high dopamine, and increased 
ix 
 
norepinephrine. SAM supplementation may be an effective therapy for both the mitigation of retinoic 
acid-related side effects and the prevention or treatment of major depressive disorder.  
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CHAPTER 1: LITERATURE REVIEW 
Introduction to Methyl Group Metabolism 
Methyl group, folate, and homocysteine metabolism involves a series of interdependent 
pathways which, when disturbed, can reflect or cause a pathological state. Methyl groups are one-
carbon units derived from dietary nutrients, including folate, betaine, methionine, and choline, that 
must be successfully activated and transported for use in hundreds of metabolic functions. The process 
begins with the conversion of methionine, an essential amino acid, into S-adenosyl methionine (SAM), 
which can transfer a methyl group to a variety of substrates. Following this transmethylation and the 
removal of the adenosine group, SAM becomes homocysteine, which can be remethylated or 
catabolized into cysteine.  
Aberrations in methyl group metabolism have been linked to a wide variety of pathologies, 
including atherosclerosis, osteoporosis, cardiovascular disease, and mental disorders
1-3
. Clinically, high 
serum homocysteine, or hyperhomocysteinemia, is used to detect impaired methyl group metabolism. 
However, correction of hyperhomocysteinemia using nutritional supplements or dietary modifications 
has been inconsistently successful. Methyl balance is controlled by a variety of genetic, hormonal, and 
nutritional factors, and understanding the significance of each contributing pathway remains an active 
goal in research.  
Transmethylation 
 
The non-polar, sulfur-containing amino acid methionine represents a starting point for methyl 
group metabolism. Methionine reacts with ATP and methionine adenosyltransferase (MAT) to form S-
adenosyl methionine (SAM), considered the universal methyl group donor (Figure 1.1). MAT has three 
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different isoforms, which differ in their regulation, kinetics, and primary site of activity
4
. Specifically, 
 
Figure 1.1: Methioine is converted to homocysteine via a transmethylation reaction. Homocysteine can be 
remethylated in either a folate-dependent or folate-independent manner. From Williams & Schalinske5. 
MAT I and MAT II are regulated via product inhibition by SAM and are nearly saturated under normal 
methionine levels. In contrast, MAT III is not regulated by SAM, and can thus function under higher 
methionine levels. MAT II is expressed in extrahepatic tissues, while MAT I and III are functional in the 
liver. 
Numerous methyltransferases catalyze the transfer of a methyl group from SAM to a substrate, 
forming S-adenosyl homocysteine (SAH) and methylated substrate. The broad range of 
methyltransferase enzymes and potential substrates illustrates the necessity of transmethylation 
reactions and the body’s reliance on available methyl groups. Methylation is a key post-translational 
modification essential for protein function, while methylation of lipids produces essential components 
of plasma membranes. Methylation of small molecules influences neurotransmitter synthesis, cell 
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signaling, and numerous other important functions. Epigenetic modifications, including methylation 
patterns of RNA and DNA, control gene expression and are increasingly recognized as contributors to 
health and disease. Given the essentiality of SAM, the primary methyl group donor, it is imperative that 
these methyltransferase reactions be regulated. To that end, the ratio of SAM to its post-reaction 
metabolite, SAH, can inhibit SAM-dependent reactions. Glycine N-methyltransferase is an enzyme 
primarily expressed in the liver, kidney, and pancreas that can help maintain the SAM:SAH ratio
6,7
. It 
functions by converting glycine to sarcosine, thus forming SAH from SAM. The SAM:SAH ratio therefore 
serves as an gauge of transmethylation potential.  
Homocysteine is formed from SAH following the removal of the adenosyl group by SAH 
hydrolase. The two major contributors to the formation of homocysteine are phospatidylethanolamine 
N-methyltransferase (PEMT), which synthesizes phosphatidylcholine, and guanidinoacetate N-
methyltransferase (GAMT), which synthesizes creatine. Collectively, PEMT and GAMT account for 
roughly 85% of SAM-dependent transmethylation
8
.  
Homocysteine can be converted to cysteine by vitamin B6-dependent enzymes cystathionine β-
synthase (CBS) and cystathionine γ-lyase or recycled by two separate remethylation pathways (Figure 
1.1). Conversion to cysteine represents a catabolic process by which homocysteine is converted first to 
cystathionine via condensation with serine, then to cysteine or other metabolites, such as glutathione, 
pyruvate, and taurine. CBS activity is positively and allosterically regulated by SAM; therefore, increased 
production of homocysteine should correspond with an increase in catabolism.  
Folate-Dependent Remethylation  
Homocysteine can be remethylated in a folate-dependent manner to form methionine. This 
process requires 5,10-methylenetetrahydrofolate (5,10-CH3-THF), which is irreversibly converted by 
methylenetetrahydrofolate reductase (MTHFR) to 5-methyltetrahydrofolate (5-CH3-THF). This 
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conversion is dependent on availability of folate groups, which cannot be formed de novo by mammals 
and must therefore be obtained in the diet. Methionine synthase (MS), which is dependent on vitamin 
B12, catalyzes the transfer of the methyl group from 5- CH3-THF to homocysteine, forming 
tetrahydrofolate (THF) and methionine. 
 The products and substrates for these remethylation reactions can control and are themselves 
controlled by transmethylation reactions. Specifically, SAM allosterically inhibits MTHFR, while  5- CH3-
THF formed by MTHFR can inhibit GNMT
6
. If methyl group supply is low, low levels of SAM will not 
inhibit MTHFR, creating elevated levels of 5- CH3-THF. 5- CH3-THF can bind and inhibit GNMT, thereby 
lowering transmethylation and increasing intracellular SAM
6
. When methyl group supply is high, 
elevated SAM inhibits MTHFR, which lowers the production of 5- CH3-THF, thus increasing GNMT activity 
and increasing the consumption of SAM. The reciprocal regulation of transmethylation and folate-
dependent remethylation allows for finely tuned control of methyl group availability.  
Folate-Independent Remethylation 
Homocysteine can also be converted to methionine using betaine, a derivative of choline. In this 
pathway, betaine-homocysteine S-methyltransferase (BHMT) transfers a methyl group from betaine to 
homocysteine, forming methionine and dimethylglycine (DMG). As in folate-independent remethylation, 
this process is regulated by dietary intake of methyl groups, availability of B-vitamins, and the SAM:SAH 
ratio. Dietary choline is oxidized to betaine, which provides the methyl group for the BHMT reaction. If 
dietary protein supply is in excess, the resulting elevated SAM inhibits BHMT activity to normalize 
methyl group supply. Correspondingly, if dietary methionine is low, BHMT expression increases to 
preserve methyl groups
9
. In contrast to folate-dependent remethylation, which occurs in all tissues, 
betaine-dependent remethylation is mostly limited to the liver and kidney.  
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Disruption of Methyl Group Metabolism and Pathology  
 
 As evidenced by the variety of regulatory factors discussed, maintenance of methyl group 
metabolism is essential for good health. The foundation of the pathway lies in sufficient dietary intake of 
several nutrients, including folate, B6, B12, choline, and protein. 
 Folate deficiency in pregnant women has been shown to cause a variety of birth defects, 
specifically improper closure of the neural tube, causing debilitating and lethal problems like spina 
bifida. In 1998, the United States mandated the enrichment of all cereal grains and grain products with 
folic acid, a public health initiative that decreased the rate of neural tube defects by 25 percent
10
. Other 
countries have similar mandates. Deficiencies in B6 and B12 contribute to depression, anemia, cognitive 
changes, and elevated homocysteine. Likewise, choline deficiency can result in impaired liver function 
and elevated homocysteine. Homocysteine is thought to be a biomarker, causal factor, or both in 
numerous pathologies. Specifically, homocysteine is an independent risk factor for cardiovascular 
disease, a fact supported by numerous human studies and animal studies utilizing genetic and diet-
based alterations to methyl group metabolism
1,11,12
. Hyperhomocysteinemia is thought to mediate 
cardiovascular damage by promoting oxidative stress and endothelial cell dysfunction. Elevated 
homocysteine has also been implicated in osteoporosis, Parkinson’s disease, Alzheimer’s disease, 
depression, diabetes, and autoimmune disorders.  
Methyl balance can also be dramatically changed by genetic factors. For example, the common 
MTHFR single nucleotide polymorphism C677T causes an accumulation of 5- CH3-THF, blocking its use in 
other biologically significant reactions. This “methyl trapping” can also result from a diet deficient in B12, 
which is required for MS functionality. Both the C677T polymorphism and low dietary B12 have been 
shown to cause hyperhomocysteinemia
13,14
. Likewise, genetic defects in CBS and cystathionine γ-lyase, 
6 
 
termed homocysteinuria, result in elevated serum homocysteine and excretion of homocysteine in the 
urine
15
. 
Previously, our lab has shown that retinoid therapy can substantially impact methyl group 
metabolism. Administration of retinoic acid has been shown to increase both GNMT abundance and 
activity, an effect specific to the liver
16
. This was accompanied in another study by DNA 
hypomethylation
17
. Retinoid therapy also appeared to support normal BHMT activity in diabetic rats and 
modulate serum homocysteine in adrenalectomized rats
18
. Given these effects, it is important to further 
characterize the effects of retinoic acid administration and potential methods to abrogate their impact 
on methyl balance.  
Retinoid Therapy 
Introduction to Retinoid Compounds 
Since its discovery in 1915, Vitamin A and its related compounds and derivatives have been 
widely studied for nutritional and therapeutic purposes
19
. The term Vitamin A refers to several fat-
soluble retinoid compounds, all containing a beta-ionone ring with an attached isoprenoid chain. These 
can be consumed from animal sources as retinyl esters and from plant sources as carotenoids, which are 
then converted to retinol on a limited basis
20
. Following enzymatic digestion in the stomach and 
intestine, retinyl esters and protein-bound carotenoids are converted to free retinol and free 
carotenoids, incorporated with bile into a micelle, and absorbed into an enterocyte. Once in the 
enterocyte, carotenoids can be converted to retinal. Retinal is either incorporated with cellular retinol 
binding protein II (CRBPII) and a fatty acid to form CRBPII-retinyl palmitate, or converted into retinoic 
acid, bound to albumin, and released to portal circulation. Similarly, free retinol is packaged with a fatty 
acid and CRBPII into CRBPII-retinyl palmitate. This complex is incorporated into a chylomicron to enter 
lymphatic circulation. Within the hepatocyte, retinoid compounds have several fates. Retinyl esters are 
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hydrolyzed, releasing free retinol and fatty acids. The free retinol can be re-esterified and stored as 
retinyl ester. Alternately, free retinol can be released into the bloodstream with retinol binding protein 
(RBP), converted to CRBP-retinal and then retinoic acid, or conjugated with glucuronic acid for excretion 
in the bile
21
. Once released into the blood, the RBP-retinol complexes with transthyretin for transport to 
the target tissue. If transported to the eye, retinol is converted to retinal, which is essential for the 
production of rhodopsin in the photoreceptor rod cells. In other cells, retinol can be converted to 
retinoic acid and attached to cellular retinoic acid binding protein (CRABP) or intracellular lipid-binding 
protein. Once transported into the nucleus and released from binding proteins, retinoic acid binds 
retinoic acid receptor (RAR) before forming a heterodimer with retinoid X receptor (RXR) and docking at 
a retinoic acid response element (RARE) on DNA to modulate gene expression
22
. In this way, retinoic 
acid can powerfully increase cell proliferation, apoptosis, differentiation, and turnover.  
Importantly, Vitamin A is a fat soluble vitamin that can be stored in the body, primarily in the 
liver as retinyl ester. This is highly beneficial in cases of Vitamin A deficiency: a supplement containing 
200,000 IU can meet the patient’s daily requirement for four to six months
23
. Because Vitamin A 
deficiency is rare in the developed world, this technique is typically utilized by humanitarian 
organizations in southwestern Asia, equatorial Africa, and Central America, where vitamin A deficiency is 
a serious public health issue. However, excessive vitamin A stored in the liver can be highly toxic, causing 
extreme skin and eye dryness, changes in blood lipids, and liver damage, including steatosis and 
fibrosis
24,25
.  
Therapeutic Retinoid Compounds 
All-trans retinoic acid 
All-trans retinoic acid (ATRA), also called tretinoin, is available as a prescription drug and widely used as 
an acne treatment. As a form of Vitamin A, ATRA interacts with retinoic acid receptors to modify gene 
 expression. Inducing the rapid turnover of epithelial cells has proved an effective therapy, both topically 
to be caused by chromosomal translocation, involving 
the promyelocytic leukemia gene, which prevents proper differentiation of myeloid cells. ATRA 
encourages the differentiation of promyelocytes,
ATRA has also been shown to effectively promote apoptosis and inhibit growth of human 
cells by down-regulation of Bcl-2, an anti
to ATRA therapy include ovarian cancer, bladder cancer, neuroblastoma, squamous cell carcinoma, an
several others
28,29
. 
13-cis retinoic acid 
In the early 1960s, pharmaceutical company Hoffman
developed a new, synthetic retinoid known as 13
acne in 1971, but dismissed the drug as a reasonable acne treatment because of the high rate of birth 
defects in his test subjects. Later, Drs. Gary Peck and Frank Yoder began evaluation of isotretinoin a
therapy for keratinization disorders, particularly lamellar 
autosomal disorder in which an infant is born with a co
reveal scaly, hyperkeratinized skin. 
Figure 1.2: All-trans retinoic acid (ATRA).
Figure 1.3: 13-cis retinoic acid (13CRA) also 
called isotretinoin 
8 
and orally, for acne vulgaris and keratosis pilaris. A
ATRA was shown to successfully treat acute promyelocytic 
leukemia (APL), retinoid therapy has been investigated for 
the treatment of several forms of cancer
the fusion of the retinoic acid receptor gene and 
 thus reducing the development of oncogenic cells
-apoptotic protein
27
. Other tumoral diseases that respond well 
-La Roche (now known as Roche in North America)
-cis retinoic acid or simply isotretinoin
Information on the early development and testing of the 
drug is varied and contradictory. Dr. Werner Bollag, a 
Swiss scientist, performed the initial exploration of the 
drug and discovered its incredible potency in treating 
ischthyosis
30
. Lamellar ischthyosis is a rare 
llodian membrane, which sheds within weeks to 
Isotretinoin was highly effective at clearing the hyperkeratinized skin 
 
fter 
. APL is thought 
26
. 
breast cancer 
d 
 
 (figure 1.3).  
s a 
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lesions. During trials for the treatment of lamellar ischthyosis, Peck and Yoder noticed that acne lesions 
were also cleared. Undeterred by the teratogenic effects, they published the initial paper on the use of 
isotretinoin to treat cystic acne in 1978
31
. The Food and Drug Administration approved the use of 
isotretinoin for severe, recalcitrant acne in 1982. Marketed by Hoffman-La Roche as Accutane, the drug 
was initially well received and became known as the gold standard of last-resort care for nodular skin 
lesions.  
 However, after widespread reports of severe side effects, the safety of isotretinoin was publicly 
questioned. Because the effects of any form of retinoic acid are nonspecific and directly impact gene 
expression, usage of therapeutic retinoid compounds carries a risk of extreme systemic side effects. 
Retinoic acid is a well-established teratogen, causing severe alterations to the central nervous system, 
craniofacial structures, and growth retardation. Isotretinoin patients were initially strongly encouraged 
to avoid pregnancy during treatment, a guideline that proved ineffective due to underreporting of 
negative events and the decentralization of isotretinoin distribution following the expiration of 
Hoffman-La Roche’s patent in February 2002
32
. In the United States, a program restricting the 
prescription of isotretinoin was instated in 2000 and updated in 2006. Female patients were required to 
take pregnancy tests monthly prior to filling their prescription and complete an online questionnaire 
confirming their knowledge of teratogenic effects and birth control. However, other side effects were 
less predictable and poorly managed, including dramatic changes in blood lipids
33,34
, chronic dry eyes
35
, 
bowel inflammation
36
, loss of night vision
35
, impairment of bone turnover, and depression
37
.  The link 
between isotretinoin and depression came into the national spotlight after B.J. Stupak, the 17-year-old 
son of U.S. Representative Bart Stupak, died from a self-inflicted gunshot wound in 2000 after several 
weeks of isotretinoin usage. Adamant that his son was a happy, popular, and well-liked student, Stupak 
claimed that isotretinoin was responsible for B.J.’s death. Although the U.S. FDA Adverse Events 
10 
 
Reporting System confirmed nearly 450 reports of depression in patients taking isotretinoin between 
1982 and 2001, including 40 suicides, it has been speculated that these events are underreported
38
.  
 The link between isotretinoin and depression is disputable and poorly understood. Hoffman-La 
Roche and many others argue that severe acne, not Accutane, causes severe depression, low self-
esteem, and poor self-image, all of which are related to suicidal ideation
39,40
. Additionally, the majority 
of Accutane users are adolescents or young adults, a population widely understood to be at a higher risk 
for depression and suicidal ideation.  
This debate spurred a variety of investigations into the effects of retinoid compounds on mood 
stability, both in cell line and animal models. Four behavioral tests are thought to best evaluate 
depression in animal models
41
. First, the forced swimming test measures behavioral despondency, with 
shorter swimming durations indicating hopelessness
42
. Second, voluntary intake of a saccharin solution 
measures anhedonia, or a loss of pleasure from activities. Third, an open field test, in which the animal 
is placed in an enclosed space and monitored for movement and willingness to explore, demonstrates 
anxiety
43
. Fourth, the tail suspension test, which measures immobility in rodents when suspended only 
by their tails, can be used as a more general indicator of mood in development of antidepressants
44
. In 
2005, forced swimming, open-field, and saccharine consumption tests were used to evaluate behavioral 
effects of oral retinoic acid treatment in a rat model. Rats administered either ATRA or isotretinoin at 
extremely high doses (10-15 mg/kg bw and 7.5-22 mg/kg bw) did not demonstrate any increases in 
depressive behavior after 6 to 10 weeks of daily treatment
45
. A follow-up study using similar doses and 
15 to 19 weeks of treatment also indicated no changes in depressive related behavior
46
.  
However, in 2006, O’Reilly and others showed that six weeks of isotretinoin treatment at 1 
mg/kg bw, comparable to human prescribed doses of 0.5 to 2 mg/kg bw, increased depressive behavior 
11 
 
in mice. Mice receiving isotretinoin displayed markedly different responses in both tail suspension and 
forced swimming tests
37
.  
Furthermore, in vitro measurements of brain tissue have shown that isotretinoin interferes with 
the trafficking and metabolism of serotonin, a neurotransmitter considered essential for maintenance of 
a “good mood.” Among the changes were increased serotonin receptor 1A (5-HT1A) and increased 
serotonin transporter (SERT), which indicates lower synaptic serotonin concentration, thought to be a 
major contributor to major depressive disorder
47
. Retinoic acid compounds have also been shown to 
impede neurogenesis and regulate both dopaminergic and noradrenergic signaling in development brain 
tissue, all of which can affect mood stability
48-51
. 
 Although the U.S. national registration program for isotretinoin patients was updated to include 
a standard screening for depressive thoughts, Hoffman-La Roche has never publicly acknowledged the 
risk of depression or suicide associated with their product. However, following a large class-action 
lawsuit won by isotretinoin patients who developed inflammatory bowel disease, the company ceased 
distribution in the United States
52,53
. Generic isotretinoin is still readily available by prescription, though 
patients with a personal or family history of mood disorders are generally advised to pursue other 
treatments.  
Major Depressive Disorder  
Major depressive disorder, more commonly referred to as depression, is a mental illness 
affecting an estimated 7-14% of all American adults every year
54,55
. Because this figure only reflects 
reported cases of depression, a poorly recognized and highly stigmatic disease, the true number of cases 
may be much higher. The American Psychiatric Association states the symptoms as a pervasively low 
mood that adversely affects everyday life for an extended period of time. Major depressive disorder is 
the leading worldwide cause for work hours lost due to disability, and women are nearly 50% more 
12 
 
susceptible than men
56
.  Persons affected by major depressive disorder experience difficulty focusing on 
tasks, eating regularly, and maintaining a normal sleep schedule. If left unmanaged, depression leads to 
suicide, which consistently ranks as a top cause of death worldwide.  
Researchers have hypothesized two main physiological bases for the development of 
depression. The first is decreased hippocampal neurogenesis as a result of stress
57
. Increased 
glucocorticoid levels can impact cell proliferation, differentiation, and survival in two specific 
regenerative regions of the brain, the olfactory bulbs and the dentate gyrus of the hippocampus. In turn, 
hippocampal atrophy can impact mood. Decreases in hippocampal volume have been shown to 
correlate with total lifetime length of depression (rather than age) in several MRI studies comparing 
depressed patients, recovered depressed patients, and healthy controls
58,59
. The second proposed 
theory is a “chemical imbalance” in the neurotransmitters that control mood. This “Monoamine 
Hypothesis” proposes that malfunctions in the synthesis, release, uptake, and degradation of 
neurotransmitters may result in a prolonged debilitative mental state. Since its proposal in 1965 by 
Joseph Schildkraut, the Monoamine Hypothesis has guided development of drug therapies
60
. Early 
compounds included monoamine oxidase inhibitors (MAOIs), which block the degradation of mood-
related neurotransmitters, and tricyclic antidepressants (TCAs), which impede transport of serotonin 
and norepinephrine. Given the risk of severe side effects, MAOIs and TCAs have largely been replaced by 
selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), and 
norepinephrine-dopamine reuptake inhibitors (NDRIs)
61
. These selective reuptake inhibitors are 
generally considered safer. Selective reuptake inhibitors block binding sites on neurotransmitter 
transporters or receptors, leading to an effective increase in synaptic serotonin, dopamine, or 
norepinephrine.  
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Currently, depression is diagnosed according to the results of the Hamilton Rating Scale for 
Depression (HAM-D), a structured interview originally developed in 1960
62
. Although widely considered 
the “gold standard” for diagnosis, the efficacy and consistency of the scale is often debated
63,64
. The 
HAM-D involves both patient responses and a clinician’s observations and includes assessment of 
agitation, changes in appetite, and changes in ability to focus on tasks
65
.  Interview responses are scored 
by severity, and the sum score is used to indicate depression. Though 20 is the accepted threshold score 
required for inclusion in a clinical trial, many clinicians disagree, further undermining the validity of the 
scale. The interview is periodically repeated throughout treatment to measure improvement or 
regression.  
Because no objective biomarker currently exists for the diagnosis of depression, much less the 
identification of specific defects in brain chemistry, many patients try several different types of 
antidepressants before experiencing relief. In fact, it is estimated that only 30-40% of patients achieve 
complete remission after starting an initial antidepressant regimen
66
. The prevalence of treatment-
resistant depression has spurred the development of augmentative therapy, or the combination of an 
antidepressant with talk-based therapy, nutritional supplements, another type of antidepressant, or 
other alternative therapies
67
.  
Serotonin 
 
Perhaps the most widely researched mood-related neurotransmitter is serotonin, a tryptophan-
based monoamine synthesized both by the serotonergic neurons of the central nervous system and by 
the enterochromaffin cells of the gut in a reaction requiring B6 (pyridoxal phosphate; Figure 1.4)
68,69
. Gut 
serotonin is absorbed into the bloodstream and stored in platelets, and its activity appears to promote 
wound healing via vasoconstriction
69
. Brain serotonin is associated with mood, appetite, sleep, learning, 
and memory
70
.  
 In 1975, research into modulation of neurotransmitter transporter (NTT) activity exploded when 
scientists at Eli Lilly developed and screened derivatives of diphenhydramine, an antihistamine with 
some antidepressant properties, for 
displayed high selectivity for serotonin transporter inhibition and was revealed to have a number of 
antidepressant effects, included increased hippocampal neurogenesis
known as fluoxetine and traded as Prozac. Although fluoxetine was not the first SSRI approved in the 
United States, it was the most aggressively marketed and widely tested, and Prozac 
collective synonym for antidepressant medications. Modulation of serotonin reuptake remains a 
Figure 1.4: Synthesis of serotonin (5-HT) 
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Serotonin is released into the synaptic 
cleft by the presynaptic cell using vesicular 
transport. Following release, synaptic serotonin 
can be recycled back into the presynaptic 
neuron by the serotonin reuptake transporter 
(SERT), taken up via serotonin receptors into 
the postsynaptic neuron for response 
propagation, taken up by presynaptic 
autoreceptors to indicate synaptic 
concentrations, or degraded, chiefly via 
catechol-O-methyl transferase (COMT) and 
monoamine oxidase (MAO; Figure 1.5
levels of synaptic serotonin have been shown to 
cause depressive symptoms
71
. 
enhanced selectivity for neurotransmitter transporters. Lilly 110140 
72,73
. The compound became 
has since become
)
68
. Low 
 
 a 
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preeminent target for drug development. 
 
 Figure 1.5: Neurotransmitter signaling 
Dopamine  
 
Dopamine is a monoamine neurotransmitter strongly linked to reward-based satisfaction. It is 
synthesized in neurons and the adrenal medulla from tyrosine or phenylalanine (Figure 1.6). Pleasurable 
activities cause a rapid release of dopamine in the brain, leading to feelings of well-being and happiness. 
Highly addictive drugs, including cocaine and methamphetamines, cause a similar but intensified 
response, and dopamine metabolism is thought to be a chief contributor to physical addiction
74
. Low 
dopamine levels are linked to a wide variety of diseases, chiefly depression, schizophrenia, and 
Parkinson’s disease
75,76
. Of these, Parkinson’s disease is considered the most degenerative, as the loss of 
motor control and tremors characteristic to the disease are very difficult to control with medication 
without severe side effects.  
 Modulation of dopamine synthesis, trafficking, and degr
treatment of these diseases. Dopamine metabolism closely mirror
specific dopamine transporter (DAT) and postsynaptic receptors. Impaired dopamine trafficking results 
Figure 1.6: Synthesis of dopamine and 
norepinephrine. 
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adation is essential for the effective 
s serotonin metabolism, utilizing a 
in severe disruption of both motor control and cognitive 
function, as observed in patients suffering from
disease. Parkinson’s disease is usually characterized by a 
loss of motor control, often manifested as “tremors,” an 
involuntary trembling in the hands. Levodopa, or L
a dopamine precursor that can cross the blood
and is used to manage Parkinson’s disease symptoms. 
However, L-DOPA also causes a large variety of side effects, 
including impaired methyl group metabolism, hypertension, 
and arrhythmia
77
.   
Recently, regulation of dopaminergic signaling
pharmaceutical intervention has been shown to treat 
depression and hyperactivity disorders, aid in smoking 
cessation, and reduce addictive cravings
78
. These drugs, 
known as norepinephrine-dopamine reuptake inhibitors 
(NDRIs), block the action of NET and of DAT,
reuptake
79
. As a relatively new class, NDRIs are considered 
atypical depressants and are often combined with more 
traditional therapies. The most popular NDRI
(marketed as Wellbutrin) is approved for treatment of 
 Parkinson’s 
-DOPA, is 
-brain barrier 
 via 
 inhibiting 
, bupropion 
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depression and for smoking cessation, but is used off-label to treat addiction, sexual dysfunction, and 
obesity
80
.  
Norepinephrine 
 
Norepinephrine is a catecholamine synthesized from dopamine in medullary chromaffin cells
81
. 
The synthesis reaction requires methyl group donation from SAM. As part of the sympathetic response, 
norepinephrine stimulates increased heart rate, increased blood pressure, and increased blood supply 
to the brain. Given these effects, norepinephrine is thought to contribute to mood balance by regulating 
motivation, pleasure, and attention (Figure 1.7)
71,82
. Norepinephrine is released and metabolized similar 
to serotonin and dopamine, but utilizes a specific norepinephrine transporter (NET) and adrenergic 
receptors. Norepinephrine is degraded by COMT and MAO, but can also be converted to epinephrine by 
phenylethanolamine N-methyltransferase (PNMT)
81
. Given its structural similarity to dopamine, drugs 
designed for either often have crossover effects.  
Selective norepinephrine reuptake inhibitors (SNRIs), including Cymbalta, Effexor, and Lexapro, 
have gained popularity for treatment of 
depression with concurrent general anxiety 
disorder and are often combined with SSRIs for 
nonresponsive patients
61
.  
Neurotransmitter Transporters and 
Depression 
 
 Because most pharmaceutical 
depression treatments revolve around 
modulation of neurotransmitter transporters Figure 1.7: Emotional regulation via serotonin, dopamine, 
and norepinephrine 
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(NTTs), it is important to discuss the activity and regulation of monoamine NTTs. As previously 
mentioned, serotonin, norepinephrine, and dopamine each utilize a specific transporter (SERT, NET, and 
DAT, respectively). SERT, NET, and DAT are all sodium/chloride dependent members of the solute carrier 
superfamily (SLC), which are anchored to the plasma membrane of monoaminergic neurons
83
. Following 
vesicular release of neurotransmitters into the synaptic cleft, NTTs transport a large portion of the 
released neurotransmitter back into the presynaptic cell, effectively lowering the synaptic concentration 
of that neurotransmitter and contributing to the presynaptic pool. NTT-facilitated reuptake is the 
primary regulatory mechanism by which cellular stores of serotonin, dopamine, or norepinephrine are 
maintained.  
Knockout (KO) models in mice have consistently demonstrated the essentiality of NTT function. 
Although it may seem counterintuitive, given that selective inhibition of NTTs by antidepressant drugs 
increases synaptic neurotransmitter concentration and generally relieves depression, NTT-KO mice have 
marked decreases in whole brain neurotransmitter concentration. For example, one study showed that 
DAT-KO mice had 95% less whole brain dopamine than wild-type controls, even when dopamine 
synthesis was more than doubled, indicating the importance of dopamine reuptake to maintain 
presynaptic stores of dopamine
84
. These mice also displayed severe hyperactivity and could be calmed 
by amphetamine administration, a response mirrored in attention-deficit/hyperactivity disorder (ADHD) 
and opposite of the expected response in a healthy subject. Similarly, NET SNPs contribute to 
depression
82
. NET-KO mice display hyperactivity, similar to DAT-KO mice; however, this is accompanied 
by excessive sympathetic responses to stimuli, including tachycardia.  
Similar responses are seen in SERT-KO mice, with anxiety-associated behaviors replacing 
hyperactivity, and SERT alterations have been implicated in several mental disorders. The promoter of 
the SERT gene contains a polymorphic region, which produces either short or long repeats. The short 
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repeats are associated with susceptibility to anxiety and depression in humans
85
. Single nucleotide 
polymorphisms (SNPs) in the SERT gene are associated with bipolar disorder, autism, obsessive-
compulsive disorder, eating disorders, and depression
86,87
. Additionally, certain SERT polymorphisms 
have been linked to both depression and non-response to SSRIs.  
Recreational drugs powerfully inhibit NTTs
84
. In particular, cocaine nonselectively inhibits SERT, 
NET, and DAT. Cocaine addiction is primarily attributed to DAT inhibition, which results in a strong 
“reward” feeling. Methamphetamines and 3,4-methylenedioxymethamphetamine (MDMA, also called 
ecstasy) impact both NET and SERT.  
Other factors that impact NTT function include glycosylation, a post-translational modification 
thought to contribute to transporter stability, and stress-related cytokines. Specifically, TNF-α, an 
inflammatory cytokine, potently promotes SERT activity
88
. As previously discussed, SSRIs, SNRIs, and 
NDRIs selectively block some NTT function, causing an increase in synaptic neurotransmitter 
concentration
61
. The mild depletion of cellular neurotransmitter concentration is tempered by receptor 
desensitization, a response that contributes to the overall antidepressant activity of the drug.  
 
Depression and Methyl Group Metabolism 
 
Impaired methyl group metabolism has long been associated with psychiatric symptoms. In 
1975, analysis of 272 patients at a mental health facility showed that depressed patients had low serum 
levels of folate, while psychotic patients had low serum B12
89
. Further studies showed that high plasma 
homocysteine and low serum folate both increased the risk of depression and increased the duration of 
depressive episodes, an effect that is especially pronounced in pregnant and postpartum women
90-92
. 
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Supplementation with folate and B-vitamins has been moderately successful in relieving depressive 
symptoms.  
Because patients with low serum folate and hyperhomocysteinemia also have low SAM levels, it 
has been suggested that oral supplementation of SAM, the ubiquitous methyl donor, may alleviate or 
prevent depression. Several clinical trials have shown that SAM is an effective antidepressant, and 
superior to some selective serotonin reuptake inhibitors
93-95
.  The use of SAM as an antidepressant is 
especially attractive for its low cost, wide availability, and high tolerability
96
. Marketed as AdoMet, SAM-
e, and adementionine, SAM has been used for the treatment of depression for over twenty years in 
Europe but has only recently become available in the United States. Interestingly, SAM supplementation 
does not increase serum homocysteine in humans, contrary to expectation
97,98
.  
The specific mechanism of antidepressant activity caused by SAM is under debate. Because SAM 
and other compounds essential to methyl group balance are required for neurotransmitter synthesis, it 
may be a simple question of methyl group supply
99
. Acute intraperitoneal SAM administration has been 
shown to transiently increase serotonin in the rat forebrain at supraphysiological doses (>200mg/kg 
bw), an effect that was matched by increased degradation into 5-hydroxyindolacetic acid (5-HIAA)
100
. 
Other groups have shown that acute intraperitoneal SAM administration at lower doses (10 mg/kg bw) 
modifies dopamine and norepinephrine metabolism inconsistently across brain regions. Using mice 
genetically modified (via ApoE knockout) to be prone to seizures, supplemental SAM was shown to 
reduce aggressive behaviors and seizure frequency
101
. Most studies have focused on clinical trials of 
SAM in depressed patients rather than the molecular mechanisms of the supplement’s activity.  
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CHAPTER 2: ORAL ADMINISTRATION OF RETINOIC ACID LOWERS 
BRAIN SEROTONIN CONCENTRATION IN RATS 
 
Abstract  
 
Major depressive disorder has been associated with lowered functionality of serotonin, dopamine, and 
norepinephrine in the brain. Oral retinoid therapy has been reported to induce sudden and severe 
depressive symptoms in adolescents and adults. Retinoid compounds have been shown to negatively 
impact neurotransmitter synthesis and transport in vitro, while animal models of retinoid therapy and 
brain health have traditionally utilized intraperitoneal administration of retinoic compounds and focused 
on depressive behaviors. To our knowledge, no previous in vivo studies have used oral administration to 
demonstrate the impact of retinoid compounds on neurotransmitters in the rat brain. In this study, male 
Sprague-Dawley rats received oral administration of either all-trans retinoic acid, all-trans retinoic acid 
plus S-adenosyl methionine (SAM), or vehicle daily. After 9 days, rats were sacrificed and brain tissue 
was collected for analysis. Rats receiving all-trans retinoic acid had a significant (48%; p<0.05) decrease 
in brain serotonin concentrations compared to control, an effect that was partially prevented by SAM 
supplementation. Neither norepinephrine nor dopamine levels were impacted by oral dosage of all-
trans retinoic acid. To our knowledge, this is the first demonstration of lowered brain serotonin 
concentrations resulting from oral administration of retinoic acid. SAM represents a potential 
therapeutic strategy to prevent major depressive disorder owing to retinoid usage.  
Introduction 
 
Recent developments in pharmacology have shown retinoid compounds to be highly effective 
for the treatment of nodular skin lesions and several cancers
102
. Of particular interest is retinoic acid, the 
most potent form, which has powerful effects on gene expression and has been successfully utilized as 
22 
 
an oral medication. However, the effects of retinoic acid are both strong and nonspecific, causing a 
variety of undesired side effects. Specifically, patients taking retinoic acid must be closely monitored for 
increases in blood lipids resulting from impaired liver function and sudden changes in mood or 
behavior
24
. A small but significant portion of retinoid patients experience sudden onset of depressive 
symptoms, including suicidal ideation. Although retinoic acid has been shown to alter serotonergic 
signaling and neurogenesis in vitro, the mechanism of this effect remains unclear
47,48
.  
 Impaired methyl group metabolism is well established as a hallmark of several pathologies. 
Retinoic acid has been shown to disturb methyl group metabolism by activating and inducing glycine N-
methyltransferase (GNMT)
16,18
. GNMT acts to optimize the intracellular ratio of S-adenosyl methionine 
(SAM) to its metabolite, S-adenosyl homocysteine (SAH), a primary indicator of transmethylation 
potential.  Recently, impaired methyl group metabolism has been implicated as a contributor to 
depressive symptoms. This is attributed to a deficiency or depletion of folate, other B-vitamins, choline, 
and SAM
3
. Supplementation with these nutrients has been moderately successful in treating 
depression
92
. Owing to the relationship between retinoids, impaired methyl group metabolism, and 
depression, we sought to characterize the neurological effects of retinoic acid therapy. In addition, we 
hypothesized that supplemental SAM would mitigate these consequences by correcting the depletion of 
intracellular methyl groups.  
Materials and Methods 
 
All animal studies were approved by the Institutional Animal Care and Use Committee and were 
performed according to Iowa State University Laboratory Animal Resources Guidelines. Male Sprague 
Dawley rats (N=19; Harlan Teklad, Madison, WI) weighing 100-130 g were housed singly in plastic cages 
on a 12 hr light:dark cycle. Rats were watered and fed ad libitum using a diet containing vitamin-free 
casein (20%), cornstarch (55%), glucose (15%), mineral mix (AIN93, 3.5%), vitamin mix (AIN93, 1%), corn 
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oil (5%), choline bitartate (0.2%; Sigma-Aldrich, St. Louis, MO) and methionine (0.3%; Sigma-Aldrich, St. 
Louis, MO).  Following a 10 d acclimation period, rats were randomly divided into three groups. The first 
group (n=6) received a daily oral dose of corn oil, administered via positive displacement pipet at 2.5 µl 
per gram body weight. The second group (n=6) received all-trans retinoic acid (ATRA)( Sigma-Aldrich, St. 
Louis, MO) at 30 µmol/kg bw suspended in corn oil at 2.5 µl/g bw. The third group (n=7) received the 
same retinoid dose plus 4mg/kg bw S-adenosyl methionine (SAM). The SAM (Nature Made, Northridge, 
CA) was a commercially available supplement sold as a 400 mg dose in a 1000 mg pill that was crushed 
and powdered prior to suspension in the retinoid and corn oil mixture. After 9 d, rats were fasted 
overnight and anesthetized by intraperitoneal injection of ketamine and xylazine (90:10 mg/kg bw). 
Whole blood was obtained via cardiac puncture and immediately centrifuged for the isolation of plasma. 
Whole liver, brain, and kidney tissue was snap frozen in liquid nitrogen for later analysis.  
Whole brain concentration of serotonin, dopamine, and norepinephrine was quantified using 
commercially available ELISA kits (Rocky Mountain Diagnostics, Colorado Springs, CO). For the 
assessment of serotonin, whole brain tissue was homogenized in 5 volumes (g/mL) of 0.5 Μ 
hydrochloric acid containing 1 g/L ascorbic acid. For the assessment of dopamine and norepinephrine, a 
separate homogenate was prepared in 5 volumes (g/mL) 0.01 Μ hydrochloric acid containing 1 mΜ 
EDTA and 4 mΜ sodium metabisulfite. Both homogenates were centrifuged at 10,000 × g for 10 min at 
4°C. The supernatant was collected and stored at -80°C prior to use.  
Hepatic and renal GNMT activity was assessed using a modified method of Cook and Wagner
18
. 
In summary, triplicate aliquots of 250 µg protein, plus an equivalent heat-killed control for each sample, 
were combined with a reaction mix containing 0.2 Μ Tris (pH 9.0), 5 mΜ dithiothreitol, 0.02 mΜ S-
adenosyl-L-[methyl-
3
H]methionine (PerkinElmer, Waltham, MA), and 2 mΜ glycine. After a 30 min 
incubation at 25°C, 10% trichloroacetic acid was added to stop the reaction. Activated charcoal was 
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added, vortexed, and centrifuged to remove the unreacted SAM
3
H. The supernatant was isolated and 
used for liquid scintillation counting.  
Plasma samples were derivatized for the quantification of circulating homocysteine using a 
previously described method
103
. During derivatization, N-acetylcysteine (1mΜ) was added for use as an 
internal standard. Homocysteine was assessed by HPLC, using a 100 µL injection of sample onto a 
µBondapak C18 Radial-Pak column (Waters, Milford, MA) in a mobile phase of 4% acetonitrile and 96% 
potassium phosphate buffer (0.1 Μ, pH 2.1). 
Liver and brain SAM concentrations were analyzed by the method of Bottiglieri with minor 
alterations
104
. Briefly, liver tissue was homogenized in two volumes of 0.4 Μ perchloric acid, while brain 
tissue was homogenized in 5 volumes (g/mL) of 0.01 Μ hydrochloric acid containing 1 mΜ EDTA and 4 
mΜ sodium metabisulfite. Liver and brain samples were injected at volumes of 80 µL and 40 µL, 
respectively, on a µBondapak C18 Radial-Pak column (Waters, Milford, MA) and a mobile phase 
consisting of 4% acetonitrile and 96% 0.1 Μ sodium acetate containing 5 mΜ heptanesulfonic acid and 
adjusted to pH 4.5. Absorbance was detected using a Waters 2487 Dual Absorbance Detector at 254 nm.  
Statistics were calculated using SigmaPlot 9.0 software (Systat, Chicago, IL). Means were 
compared using a one-way ANOVA, followed by the Fisher least significant difference post-test. When 
applicable, the means of treatment groups were compared to control using the student’s t-test.  
Results 
 
SAM supplementation lowered total weight gain, but did not affect relative liver and kidney size. Rats 
receiving SAM supplementation with ATRA gained 20% less weight than control and ATRA rats (P<0.05). 
However, relative liver and kidney sizes remained consistent across treatment groups (Table 2.1).  
25 
 
Neither ATRA nor SAM significantly changed concentrations of SAM in the brain and liver. Although 
the data suggest that ATRA may lower liver and brain SAM, HPLC analysis revealed no significant 
differences between mean group levels of SAM in the brain and liver (Table 2.2). Although SAM 
supplementation appeared to increase tissue SAM, SAM levels were greatly varied within groups. It was 
noted that liver SAM had no correlation to brain SAM in individual rats. Furthermore, the SAM:SAH ratio 
was not impacted in either tissue.  
Neither ATRA nor SAM significantly changed serum homocysteine levels. While ATRA appeared to 
raise serum homocysteine, this effect was not statistically significant. As with the tissue concentrations 
of SAM, the levels of serum homocysteine were varied within groups. SAM did not alter homocysteine 
levels (Table 2.2).  
Retinoic acid caused elevated hepatic GNMT activity. In accordance with similar studies in our lab, 
ATRA increased hepatic GNMT activity by 129% (p<0.05) regardless of SAM supplementation (Figure 
2.1). As expected, this result was tissue specific; renal GNMT was not significantly impacted by ATRA or 
by SAM.  
Retinoic acid lowered whole brain serotonin, but did not affect norepinephrine and dopamine. Oral 
supplementation of ATRA lowered whole brain serotonin by 46% (p<0.05), an effect that was partially 
attenuated by SAM (Figure 2.2 A). In contrast, ATRA did not significantly impact whole brain 
concentrations of norepinephrine and dopamine (Figure 2.2 B,C).  
Discussion 
  
 Previous studies have shown that chronic administration of retinoic acid induces depressive 
behaviors in mice
37
. Changes in neurotransmitter synthesis and transport are regarded as the 
physiological basis for mood disorders. Of particular interest are serotonin, norepinephrine, and 
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dopamine, the three neurotransmitters that have been successfully targeted by pharmaceutical 
intervention for the treatment of depression. Serotonin modulates numerous behavioral and emotional 
processes, including mood, anger, attention, and memory. In the present study, oral administration of 
ATRA was shown to lower whole brain serotonin, providing a partial biochemical basis for the 
correlation of mood changes with retinoid therapy. However, this finding is in direct contrast to the 
literature
47
. In vitro studies involving retinoic acid and serotonin metabolism suggest that retinoic acid 
may affect the stability of serotonin mRNA or the stability of its transporter and receptor mRNA 
transcripts, showing a possible mechanistic basis for the reduced whole brain serotonin
47
. 
 ATRA did not appear to affect whole brain concentration of norepinephrine and dopamine. 
Dopamine is primarily produced in two regions of the brain, the substantia nigra and the ventral 
tegmental area, while norepinephrine is produced from dopamine by specialized chromaffin cells. 
Because our homogenate was prepared from the whole brain rather than of one region, changes in 
norepinephrine and dopamine concentrations could have been masked.  
 SAM administration did not affect levels of serotonin, norepinephrine or dopamine, an effect 
that is somewhat surprising given the role of SAM in the synthesis of norepinephrine from dopamine, 
tyrosine, and phenylalanine and its overall use as a successful antidepressant. Furthermore, we would 
expect successful SAM administration to increase whole brain and liver SAM concentration.  However, 
problems with the administration of SAM could have prevented proper absorption of the compound and 
prevention of its activities. This is supported by the inconsistencies in SAM concentrations in the liver 
and brain within the group receiving supplemental SAM. While the marked increase in hepatic GNMT 
activity confirms the successful administration of retinoic acid, the oil based vehicle poorly suspended 
the powdered SAM and was not well tolerated. Rats receiving ATRA developed skin lesions at the point 
of contact with the positive displacement pipet, an effect that seemed exacerbated by the addition of 
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powdered SAM to the mixture. Furthermore, as a sulfur-containing amino acid, the SAM likely had a 
disagreeable taste, which could partially explain the impaired growth of the ATRA+SAM group. The 
impaired growth was not accompanied by alterations to relative liver or kidney size. In future studies, 
these challenges should be addressed to ensure consistent and tolerable administration of ATRA and 
SAM.  
 To our knowledge, this is the first demonstration that oral administration of ATRA lowers whole 
brain serotonin in rats. This further supports the importance of close monitoring of mood changes in 
patients receiving retinoid therapies. Given the inconclusive nature of our findings related to the 
concurrent administration of SAM, further research and development of an alternate administration 
vehicle are pertinent.  
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Table 2.1: SAM supplementation significantly reduces total weight gain, but does not impact relative 
kidney or liver sizes.  
 
 
Total weight gain, 
g 
Relative liver 
size, % 
Relative kidney size, 
% 
Control 128.0±3.5
a 
3.7±0.1 0.7±0.1 
ATRA 124.3±5.3
a 
3.5±0.1 0.7±0.1 
ATRA+SAM 96.6±7.1
b 
3.5±0.1 0.7±0.1 
Data shown as group mean ±SE; superscript letters indicate significant differences 
between groups (p<0.05) 
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Table 2.2: Indices of methyl group metabolism were unchanged by retinoic acid and SAM 
supplementation. 
 
 Liver Brain Plasma 
 
SAM 
nmol/g 
SAH 
nmol/g 
SAM:SAH 
SAM 
nmol/g 
SAH 
nmol/g 
SAM:SAH 
Hcy 
µmol/L 
Control 25.2±1.4 9.6±1.3 3.0±0.5 10±2.4 1.5±0.3 5.5±1.7 6.3±1.6 
ATRA 23.3±3.2 9.4±1.9 3.7±0.3 6.0±1.2 0.7±0.3 6.0±3.6 9.3±1.9 
ATRA+SAM 30.5±2.9 13.0±2.9 3.1±0.7 12.2±4.6 2.0±0.8 7.5±4.0 9.9±1.6 
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Figure 2.1: Hepatic and renal GNMT activity. Data shown as mean ±SE. Letters indicate significant 
differences between groups in a particular tissue (p<0.05).  
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Figure 2.2: Whole brain 
concentration of serotonin 
(A), dopamine (B), and 
norepinephrine (C). 
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CHAPTER 3: ORAL ADMINISTRATION OF S-ADENOSYL METHIONINE 
INCREASES MOOD-RELATED NEUROLOGIC COMPOUNDS AND 
MITIGATES LIVER DYSFUNCTION SECONDARY TO ORAL ALL-TRANS 
RETINOIC ACID AND 13-CIS RETINOIC ACID THERAPY 
 
Abstract 
 
As retinoid therapy gains popularity for the treatment of skin lesions and various cancers, it is 
increasingly important to understand the side effects and consequences of retinoid treatment, which 
include development of hepatic steatosis, alterations in blood lipids, impaired methyl group metabolism, 
and depressive symptoms. The focus of this study was the impact of all-trans- and 13-cis retinoic acid on 
one-carbon metabolism and the potential for mitigation of these effects by oral S-adenosyl methionine 
(SAM), the universal methyl group donor. Rats receiving all-trans retinoic acid had 42% increased liver 
lipids, 71% increased liver triglycerides, and 65% decreased hepatic SAM. Rats receiving 13-cis retinoic 
acid had 42% increased liver lipids, 57% increased liver triglycerides, and 39% decreased hepatic SAM. 
Both forms of retinoic acid caused moderate, but significant increases in whole brain serotonin and 
decreases in whole brain neurotransmitter transporters. These effects were partially or completely 
prevented by concurrent oral administration of SAM. In addition, SAM supplementation in healthy rats 
was shown to increase whole brain dopamine by 1,650% and whole brain norepinephrine by 70%. In 
contrast to other studies, SAM was not shown to impact serotonin levels. Our data indicates that the 
depressive effect of retinoic acid therapy may be due to a functional deficit in methyl groups as a result 
of impaired methyl group metabolism. Furthermore, oral SAM seems to be a powerful agent in the 
prevention or treatment of major depressive disorder caused by retinoic acid administration or by other 
factors.  
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Introduction 
 
As retinoid therapies gain popularity for the treatment of numerous pathologies, from skin 
lesions to cancer, it is important to characterize and understand the mechanisms of their side effects. 
Researchers have noted increases in blood lipids, hepatic steatosis, and alterations in methyl group 
metabolism after treatment with retinoid compounds
18,33
. Specifically, increases in hepatic glycine N-
methyl transferase (GNMT) and corresponding depletion of methyl groups occur following 
administration of all-trans retinoic acid. In addition, 13-cis retinoic acid (13CRA) has been linked to acute 
onset of major depressive disorder and suicidal ideation. 13CRA has been shown to modulate levels of 
serotonin and its transporter and receptors. Disruptions in methyl group metabolism have long been 
noted as causes of cognitive and mood disorders, including depression, Alzheimer’s disease, and 
Parkinson’s disease
76,105
. Supplementation with B-vitamins and folate has enjoyed moderate clinical 
success in alleviating depressive symptoms
91,92,106
. Recently, S-adenosyl methionine has been touted as a 
potential treatment for depression, both alone and in conjunction with prescription serotonin reuptake 
inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs)
94,107
. 
 Given the relationships between retinoid therapy, dysfunctional methyl group metabolism, and 
brain health, it is important to explore the potential of SAM to mitigate the side effects of retinoic acid. 
In this study, two types of retinoic acid, ATRA and 13CRA, were administered with supplemental SAM to 
characterize the impact of SAM supplementation on overall health, with a particular focus on the 
support of mood-related compounds.  
Materials and Methods 
 
Animals. All protocols were approved by the Institutional Animal Care and Use Committee and 
performed according to Iowa State University Laboratory Animal Resources Guidelines. Male Sprague-
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Dawley rats (N=37; Harlan Teklad, Indianapolis, IN) were obtained at 100-130 g, singly housed in plastic 
cages in a room with a 12 hr light:dark cycle, and given ad libitum access to food and water. The diet was 
a lower-protein formulation containing vitamin-free casein (10%), cornstarch (65%), glucose (15%), 
mineral mix (AIN93, 3.5%), vitamin mix (AIN93, 1%), corn oil (5%), choline bitartate (0.2%; Sigma-Aldrich, 
St. Louis, MO) and methionine (0.3%; Sigma-Aldrich, St. Louis, MO). After an acclimation period, the rats 
were randomly divided into six groups. The first group (n=6) received daily oral administration of honey 
thinned with distilled water (3:1) at 1.5 µL/g bw and served as a control. The second group (n=6) 
received 10 mg/kg bw crushed SAM (Nature Made, Northridge, CA) suspended in the same diluted 
honey vehicle. The third and fourth groups (n=6) received all-trans-retinoic acid (ATRA) or 13-cis-retinoic 
acid (13CRA) at 30 µmol/kg, respectively. The fifth and sixth groups received all-trans retinoic acid 
(ATRA) or 13-cis retinoic acid (13CRA), respectively, at 30 µmol/kg, plus 10 mg/kg bw crushed SAM. 
Treatment doses were based on previous retinoid studies and recommended human dosages. All doses 
were administered orally in the 3:1 honey and water mixture at 1.5 µL/g bw using a positive 
displacement pipet. After 20 daily doses, all rats were fasted overnight, anesthetized by intraperitoneal 
injection of ketamine and xylazine (90 and 10 mg/kg bw, respectively), and sacrificed. Whole blood was 
obtained via cardiac puncture and immediately centrifuged for the isolation of plasma. Liver, kidney, and 
brain tissue was collected and snap frozen in liquid nitrogen prior to storage at -80°C. 
Enzyme analysis. Assessment of hepatic and renal GNMT assessment was performed as previously 
described in Chapter 2.  
HPLC analysis. Assessment of hepatic and neural SAM and SAH was performed as described in Chapter 
2; however, both liver and brain extractions were injected at 80 µL.  
DNA methylation assessment. Global DNA methylation was assessed using a colorimetric ELISA 
(Epigentek, Farmingdale, NY). The kit utilized 100 ng of DNA, which was isolated from liver tissue using a 
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QuickGene 810 with the appropriate kit (Autogen, Holliston, MA). Results were compared to positive 
and negative controls provided by the kit and calculated according to the known methylation of the 
positive control.  
Neurotransmitter and transporter assessment. Quantification of whole brain serotonin, dopamine, and 
norepinephrine were performed as described in Chapter 2, using ELISA kits (Rocky Mountain 
Diagnostics, Colorado Springs, CO). For the detection of serotonin transporter (SERT), dopamine 
transporter (DAT), and norepinephrine transporter (NET), whole brain homogenate was prepared using 
5 volumes (g/mL) of buffer containing 0.25 Μ sucrose, 10 mΜ sodium phosphate, 1mΜ sodium azide, 
and 0.1 mΜ phenylmethylsulfonyl fluoride. Following homogenization, samples were centrifuged at 
14,500 × g for 30 min and stored at -80°C until use. Each transporter was assessed using a separate 
commercially available ELISA kit (SERT and NET: USCN Life Science Inc., Houston, TX; DAT, Bio Medical 
Assay, Beijing, China).  
Liver lipid quantification. Total liver lipid content was assessed using the Folch extract procedure
108
. 
One gram of liver tissue was added to 10 mL chloroform and methanol (2:1 v/v) and homogenized using 
a Potter-Elvehjem homogenizer, then filtered, diluted to 20 mL with chloroform:methanol, and added to 
4 mL of calcium chloride solution (0.05%). After overnight separation, the upper phase was discarded 
and the lower phase was washed. Triplicate 5 mL aliquots of the lower phase were added to weighing 
pans with a known mass. After drying overnight, the pans were weighed to calculate the extracted lipid. 
An additional 5 mL aliquot was preserved at -20°C for the analysis of liver triglycerides. Liver triglycerides 
were detected using the prepared aliquots of liver lipid and a colorimetric lipase kit (BioAssay Systems, 
Hayward, CA). Briefly, 10 µl samples were added to an enzyme mix containing lipase, ATP, and a dyeing 
reagent, allowed to incubate at room temperature for 30 minutes, and read on a Bio-Tek EL-340 
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microplate reader at 562 nm. Results were compared to standards provided by the kit and to total lipid 
concentration.  
Statistics. Statistics were calculated using SigmaPlot 9.0 software (Systat, Chicago, IL). Means were 
compared using a two-way ANOVA, followed by the Fisher least significant difference post-test. When 
variance was great, a two-way ANOVA followed by the Holm-Sidak method post-test was used to 
establish comparisons versus control. When applicable, the means of treatment groups were compared 
to control using the student’s t-test.  
Results 
 
Oral SAM supplementation is well tolerated in rats. No changes in weight gain, relative liver size, or 
relative kidney size were observed (Table 3.1).  
Retinoic acid treatment and SAM supplementation impact markers of methyl group metabolism. 
ATRA causes a 64% reduction in hepatic SAM (p<0.05), an effect that was reversed by supplemental 
SAM.A similar, but not significant decreases was observed in rats receiving 13CRA. Neither treatment 
affected the SAM:SAH ratio. SAM supplementation significantly increased brain and liver SAM in control 
rats (370% and 154%, respectively; p<0.05) but no change to the SAM:SAH ratio was observed in either 
tissue. Plasma homocysteine was not impacted by either treatment (Table 3.2).  
ATRA and 13CRA exert similar effects on hepatic and renal GNMT. Both ATRA and 13CRA caused 
similar increases in hepatic GNMT activity (60% and 80%, respectively; p<0.05). Supplemental SAM was 
able to partially alleviate the elevated hepatic GNMT activity, but this response was highly varied within 
each treatment group. Neither treatment significantly impacted renal GNMT activity (Figure 3.1).  
Neither retinoic acid nor supplemental SAM impacted global DNA methylation. No changes in the 
percentage of 5-methyl cytosine in total DNA were observed, regardless of treatment (Figure 3.2).  
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SAM supplementation increased whole brain concentration of dopamine and norepinephrine, but not 
serotonin. SAM supplementation without concurrent retinoic acid administration caused whole brain 
dopamine concentration to increase 15-fold (p<0.05) (Figure 3.3 B). While a one-way ANOVA revealed 
no significant changes in norepinephrine concentration, a student’s t-test showed that rats receiving 
SAM supplementation exhibited a 70% increase in mean norepinephrine concentration when compared 
to control rats, regardless of retinoic acid treatment (Figure 3.3 C). While serotonin concentrations 
appeared to be doubled by SAM, the effect was not significant (Figure 3.3 A). Neither retinoid treatment 
appeared to significantly alter whole brain concentration of norepinephrine and dopamine.  However, 
when compared to control using a student’s t-test, both retinoid treatments increased whole brain 
serotonin (p<0.05).  
Retinoic acid affects neurotransmitter transporter abundance. Analysis of the three corresponding 
transporters for serotonin, dopamine, and norepinephrine (SERT, DAT, and NET, respectively) revealed 
significant alterations in DAT and NET, but not SERT (Figure 3.4). ATRA lowered DAT by 30% relative to 
control, and 13CRA lowered NET by 23% relative to control (p<0.05). Both of these effects were 
completely prevented by SAM supplementation.   
Retinoid therapy increases liver lipids. Both ATRA and 13CRA induced 42% increased mean total liver 
lipid concentration (p<0.05) (Figure 3.5). Supplemental SAM blocked this effect in rats treated with 
13CRA, but not in rats receiving ATRA. Further, ATRA and 13CRA increased liver triglycerides by 71% and 
57%, respectively (p<0.05). This effect was partially attenuated by supplemental SAM.  
Discussion 
 
 Retinoid therapy has been associated with an increase in depressive episodes in otherwise 
healthy patients; however, the mechanism of this effect remains under debate. Here, we hypothesized 
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that oral administration of two forms of retinoic acid, ATRA and 13CRA, may modify neurotransmitter 
metabolism and liver health by disturbing methyl group balance. As previously demonstrated, both 
ATRA and 13CRA significantly increased hepatic GNMT activity. Accordingly, hepatic SAM was depleted 
in both retinoic acid groups.  
 Several aberrations in methyl group metabolism have been shown to contribute to hepatic 
steatosis, or an excess accumulation of fat that impedes liver function. Ethanol, low dietary methioinine, 
low dietary protein, low folate intake, and low betaine intake have all been implicated in the 
pathogenesis of the disease
109,110
. The relationship between depleted hepatic SAM supply and increased 
hepatic lipids is thought to be due to changes in the activity of two SAM-dependent enzymes, DNA 
methyltransferase and phosphatidylethanolamine N-methyltransferase. These enzymes are responsible 
for DNA methylation and the synthesis of phosphatidylcholine from phosphatidylethanolamine, 
respectively. DNA methylation is an essential component of epigenetic regulation of gene expression. 
Phosphatidylcholine is required for effective transport and synthesis of very low density lipoproteins. In 
certain conditions, including high ethanol intake and methyl group depletion, changes in these 
processes result in DNA hypomethylation and an accumulation of liver lipids. Furthermore, liver toxicity 
and elevated serum triglycerides are well-known side effects of retinoid therapy, particularly 13CRA
33,111
. 
This is thought to be due to upregulation of hepatic palmityl-CoA synthetase
112
. As expected, the group 
receiving retinoic acid had elevated liver lipids and triglycerides, and depleted hepatic SAM. 
Interestingly, supplemental SAM was able to completely attenuate liver lipids and partially attenuate 
hepatic triglycerides in rats treated with 13CRA, but only partially lessened elevation of liver triglycerides 
in rats treated with ATRA. However, no appreciable changes in DNA methylation were observed. This 
suggests that the accumulation of liver lipids could be mostly attributed to retinoic acid’s influence on 
palmityl-CoA synthetase and only moderately exacerbated by depletion of SAM. Furthermore, SAM 
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supplementation seems to be a viable preventative therapy for hepatitis steatosis, especially due to 
13CRA usage.  
 In contrast to our previous study, SAM administration had no discernible effect on weight gain, 
relative liver size, or relative kidney size. Taken with the significant increase in both liver and brain SAM, 
this data indicates that oral SAM is well tolerated in rats when administered in the appropriate vehicle.  
 The results of the neurotransmitter quantification experiments can be interpreted in several 
ways. It is important to consider not only the absolute measurement of whole brain serotonin, 
norepinephrine, and dopamine, but also the measurements in the context of their transporters. As 
previously discussed, each transporter is the chief regulator of its respective neurotransmitter 
concentration in the intracellular pool and in the synaptic space. Depressed patients have been shown 
to have low SERT, DAT, and NET. Because these NTTs are responsible for replenishing the intracellular 
neurotransmitter pool by recycling a portion of the neurotransmitter released into the synapse, low NTT 
is thought to contribute to a depressed mood by depleting total neurotransmitter levels, thereby 
lowering synaptic neurotransmitter concentration. In the context of select reuptake inhibitors, a class of 
antidepressants that bind and inhibit NTTs, lower functional NTT actually increases synaptic NT by failing 
to remove the portion that would normally be recycled into the presynaptic neuron. However, 
antidepressant treatment has been shown to blunt the activity of postsynaptic receptors, so any 
decrease in intracellular NT is matched by decreased removal by the postsynaptic cell. Therefore, the 
net effect of these antidepressants is increased synaptic serotonin, dopamine, or norepinephrine, 
contributing to a stable mood.  
 In this study, both the SAM and the retinoic acid treatments impacted neurotransmitter 
concentration, NTT concentration, or both. First, we will consider the impact on serotonergic signalling. 
In contrast to our previous study, whole brain serotonin was significantly increased in rats receiving 
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either form of retinoic acid. This matches the findings of O’Reilly, Trent, and others, who have shown 
that 13-cis retinoic acid increases intracellular serotonin in vitro
47
. However, our analysis did not reveal a 
significant change in SERT, while the O’Reilly group observed significant decreases in SERT and the 
serotonin autoreceptor 5-HT1A, which inhibits serotonergic firing. They speculated that the depressive 
symptoms associated with retinoic acid treatment are due to low synaptic serotonin, caused by declines 
in reuptake and inhibition of serotonin release. Therefore, although serotonin may be increased, it is 
largely sequestered in the presynaptic neuron. Because our study evaluated whole brain serotonin, we 
cannot definitively say whether retinoic acid treatment increased serotonin sequestration. However, 
high serotonin has been shown to increase 5-HT1A, which inhibits neuronal firing
113
. It is possible that 
the higher serotonin levels seen in rats receiving retinoic acid could have, in turn, caused lower synaptic 
release of serotonin through the inhibitory activity of 5-HT1A. 
 Although rats treated with SAM seemed to have increased whole brain serotonin, the variance 
within each group was great, and no significant difference to the control group was observed. Rats 
treated with both retinoic acid and SAM did not have increased whole brain serotonin, indicating that 
SAM attenuated changes to serotonergic signalling secondary to retinoic acid treatment. SAM treatment 
also appeared to increase SERT, but this effect was not significant, suggesting that mild increases in 
whole brain serotonin were matched by increases in SERT to stabilize synaptic serotonin. 
 Oral SAM administration was shown to significantly increase whole brain dopamine. In rats 
receiving only SAM treatment, whole brain dopamine was increased more than 15-fold, while rats 
receiving concurrent retinoic acid experienced a comparatively mild increase, roughly 2- or 3-fold. ATRA-
treated rats had normal whole brain dopamine, but lower DAT, an effect that was corrected by SAM 
therapy. In dopaminergic signalling, increased synaptic dopamine causes a compensatory increase in the 
autoregulatory D2 receptor, which inhibits neuronal firing, thereby stabilizing synaptic dopamine. This is 
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very similar to the function of 5-HT1A in serotonergic signalling. However, D2 receptors also control DAT 
funcitonality; increased D2 activity upregulates DAT activity and possibly expression. Using D2 
autoinhibition of firing and increasing DAT-mediated reuptake, sudden increases in synaptic dopamine 
can be attenuated. However, no change in whole brain DAT was seen in SAM-treated rats, indicating 
two potential outcomes. First, the regulatory capacity of D2 autoreceptors could have been overloaded 
by the extreme increase in dopamine. Second, the synthesis of dopamine could have been so high that 
reuptake was unnecessary to maintain a sufficient intracellular pool, and the excess dopamine was 
allowed to degrade. High dopamine is the chief physiological root of psychosis and mania. However, 
mildly increased dopamine is associated with feelings of reward and well-being, and the dopamine 
concentration at which positive feelings escalate to mania or psychosis is not well defined. In rats, 
chronic ketamine administration induces a psychotic state, and evaluation of dopamine levels in 
ketamine-treated rats is useful to determine the level at which increased dopamine induces psychosis. 
Some studies have reported the extracellular dopamine threshold to be 90-200% of control, and 
increases of 60% or less are not associated with psychotic behaviour in rats
114,115
. In humans, the 
threshold is not well defined. Psychotic patients have been shown to have 30% greater dopamine 
synthesis capacity than healthy patients
115
. In the same study, schizophrenic patients were found to 
have similar dopamine levels, yet no development of psychosis, a difference thought to be due to varied 
receptor sensitivity. Additionally, bupropion, a potent DAT inhibitor and widely successful 
antidepressant, has only been tenuously linked to psychosis
116
. Given the variance in reported dopamine 
levels in psychosis, both in rats and in human patients, it is difficult to define the overall effect of oral 
SAM.  
Taken together, our data indicates that SAM supplementation in healthy adults may be 
inappropriate at this dose (10 mg/kg bw). In 2012, Green and others evaluated the safety of SAM 
supplementation in patients with 22q11 deletion syndrome, a genetic mutation that causes 
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variedabnormalities, including increased risk of depression and schizophrenia, congenital heart disease, 
and cleft palate. In this population, patients were carefully monitored for psychotic and manic 
symptoms, but none were observed, even at 1600 mg/day, an incredibly high dose
117
. Additionally, 
many debilitating symptoms of Parkinson’s disease are thought to be due to low dopamine; SAM 
supplementation could be a viable treatment for Parkinson’s patients. It seems that SAM 
supplementation could be an effective therapy for those vulnerable to methylation-related neurologic 
disorders.  
 Noradrenergic signalling was impacted by 13CRA and SAM. Rats receiving 13CRA had 
significantly lower whole brain NET, but no change in whole brain norepinephrine. In contrast, SAM 
supplementation significantly increased norepinephrine relative to control, but did not impact NET. Low 
NET is associated with tachycardia and mania caused by lowered clearance of norepinephrine, which 
stimulates sympathetic effects, from the synaptic space. This effect, while rare, has been reported in 
humans taking 13CRA
118,119
. Rats receiving both SAM and 13CRA had normal whole brain NET, indicating 
that SAM supplementation may be a feasible therapy in conjunction with 13CRA in patients suspected to 
be at risk for atrial tachycardia. The significant increase in norepinephrine seen in all rats receiving SAM, 
without an increase in NET, indicates moderately higher synaptic norepinephrine. Clinically, this may 
manifest as increased focus and energy. Norepinephrine levels also provide more information regarding 
dopaminergic signalling, because norepinephrine is synthesized from dopamine in a SAM-dependent 
manner. Given the extremely elevated dopamine levels and only moderately elevated norepinephrine, it 
seems that the majority of excess dopamine is not being converted to norepinephrine.  
 The overall impact of retinoic acid and supplemental SAM on neural health is debatable. ATRA 
seemed to increase whole brain serotonin, lower DAT, and normal whole brain norepinephrine. As 
discussed, lower DAT is implicated in depression. However, increases in whole brain serotonin without a 
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concurrent increase in SERT parallel the physiologic outcome of antidepressant therapy. The effects of 
13CRA are slightly more definitive. 13CRA similarly increased whole brain serotonin, but did not impact 
dopaminergic signalling. However, 13CRA seemed to lower whole brain NET, indicating that while the 
levels of whole brain norepinephrine were normal, the synaptic norepinephrine may have been 
abnormally high. Tachycardia in 13CRA patients could be caused in part by low NET. SAM 
supplementation appeared to attenuate whole brain serotonin and mildly increase both dopamine and 
norepinephrine in rats receiving either retinoic acid treatment. Changes in neurotransmitter 
transporters were also attenuated by SAM. This suggests that supplemental SAM may prevent or treat 
depressive symptoms associated with retinoic acid therapy.  
However, SAM supplementation in healthy adults may not be advisable. Although SAM 
supplementation alone did not appear to appreciably affect serotonin and only caused a mild increase in 
whole brain epinephrine, the marked increase in dopamine is concerning. Extremely high dopamine is a 
chief biochemical cause of psychosis, and the unchanged level of DAT indicates that the autoregulatory 
mechanisms were completely overwhelmed
84
. While most SAM distributors advise against coupling 
supplemental SAM with a prescription antidepressant without the approval or monitoring of the 
prescribing physician, this is mostly due to the risk of serotonin syndrome, or a manic episode due to 
extreme elevation of serotonin. Little information on supplemental SAM and psychosis is available in the 
literature. Our results indicate that supplemental SAM may cause psychosis due to dopaminergic 
signalling. Taken together with the positive effects of SAM in retinoic acid therapy, our data suggests 
that supplemental SAM is inappropriate for healthy adults at the dosage level (10 mg/kg) in this study. 
Overall, our study showed numerous undesirable effects of retinoic acid therapy, including 
depleted hepatic SAM, development of fatty liver, and some modulation of serotonin, norepinephrine, 
and dopamine. Supplemental SAM appeared to be an excellent conjunctive therapy, preventing or 
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partially preventing nearly all negative effects of retinoic acid. However, supplemental SAM at 10 mg/kg 
did not have a convincingly positive impact on hepatic or neural health when administered to healthy 
rats. In fact, the extreme increase in dopamine may be very harmful. The use of SAM in patients at risk 
for liver disease or mental disorders may be advantageous, given the low cost and relative safety of the 
supplement, and further research in this avenue should be conducted.  
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Table 3.1: Neither retinoic acid treatment nor SAM supplementation impacts markers of metabolic 
health. 
 
 
Total weight gain 
g 
Relative liver size 
% 
Relative kidney size 
% 
    
Control 100.84±4.63
 
2.90±0.12
 
0.70±0.03 
+SAM 119.55±5.54 3.09±0.15
 
0.67±0.01 
    
ATRA 109.52±5.01 3.20±0.15
 
0.63±0.01 
+SAM 110.11±6.58
 
3.10±0.08
 
0.74±0.03 
    
13CRA 117.95±6.03
 
3.11±0.06
 
0.70±0.04 
+SAM 111.82±6.25
 
3.19±0.08
 
0.66±0.02 
Values shown are group mean ±SE. 
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Table 3.2: Retinoic acid and SAM exert opposite effects on hepatic and neural SAM concentrations.  
 Liver Brain Plasma 
 SAM 
nmol/g 
SAH 
nmol/g 
SAM:SAH 
SAM 
nmol/g 
SAH 
nmol/g 
SAM:SAH 
Hcy 
µmol/L 
        
Control 56.7±6.6
a 
26.2±7.1
a 
2.7±0.9 5.0±1.6 2.0±1.1
a 
4.6±1.4 7.0±0.5 
+SAM 100.6±12.1
b
 34.5±9.6
a 
3.9±0.8 18.5±3.6* 6.8±1.5
b 
2.8±0.3 6.0±0.6 
        
ATRA 14.9±4.1
a,
* 6.9±1.4
b 
2.2±0.5 5.5±1.4 1.2±0.5
a 
9.1±4.8 5.4±1.2 
+SAM 83.2±17.5
a,b 
22.8±10.9
a 
5.4±1.6 15.3±7.8 6.4±3.1
b 
3.1±1.3 6.9±0.5 
        
13CRA 32.0±11.6
a 
11.7±4.2
a 
3.8±1.4 7.3±1.6 3.1±1.0
a 
2.9±0.5 6.4±0.8 
+SAM 80.8±15.0
a,b 
21.2±6.3
a 
5.6±1.4 9.9±3.2 5.7±3.0
b 
8.2±4.1 6.2±0.8 
Data expressed as group mean ±SE. Superscript letters indicate significant differences between group means as 
tested by two-way ANOVA followed by Fisher’s LSD (p<0.05) while asterisks indicate significant differences to 
control using student’s t-test. 
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Figure 3.1: Retinoic acid treatment causes elevated hepatic, but not renal, GNMT activity. Supplemental 
SAM partially prevents increased GNMT activity due to 13CRA treatment. Values shown are group 
means ±SE. Letters indicate significant differences between groups.  
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Figure 3.2: Neither retinoic acid treatment nor SAM supplementation significantly impacts global DNA 
methylation. Values shown are group means ±SE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
49 
 
Figure 3.3: Whole brain 
neurotransmitter 
concentrations for rats treated 
with retinoic acid and 
supplemental SAM. Values 
shown are group means ±SE. 
Letters represent significant 
differences between group 
means (p<0.05). Asterisk 
indicates significant difference 
in group mean when 
compared to control using a 
student’s t-test (p<0.05).  
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 Figure 3.4: Whole brain 
neurotransmitter  transporter 
concentrations for rats treated 
with retinoic acid and 
supplemental SAM. Values 
shown are group means ±SE. 
Letters represent significant 
differences between group 
means (p<0.05). Asterisks 
indicate significant difference 
in group means when 
compared to control using a 
student’s t-test (p<0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
51 
 
 
 
Figure 3.5: Total liver lipids and 
triglycerides in rats treated with 
retinoic acid and supplemental 
SAM. Values shown are group 
means ±SE. Letters represent 
significant differences between 
group means (p<0.05).  
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